Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.21.2
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2021
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Product revenue comprises Journey’s seven marketed products: Targadox®, Luxamend®, Ceracade®, Exelderm®, Ximino®, Accutane® and Qbrexza®. Substantially all of the product revenue is recorded in the U.S. The Company’s collaboration revenue is from Cyprium’s agreement with Sentynl (see Note 3). The Company’s related party revenue is from Checkpoint’s collaborations with TGTX. The table below summarizes the Company’s revenue for the three and nine months ending September 30, 2021 and 2020:

Three months ended September 30, 

Nine Months Ended September 30, 

    

2021

    

2020

    

2021

    

2020

Revenue

Product revenue, net

$

19,610

$

9,447

$

45,617

$

30,808

Collaboration revenue

1,446

4,646

Revenue – related party

 

29

 

28

 

252

 

1,042

Net revenue

$

21,085

$

9,475

$

50,515

$

31,850